Diffuse large B-cell lymphoma
Conditions
Interventions
Group 1 :6*R-CHOP
Group 2:6*R-CHOP + 2*R
Group 3:6*R-CHOP + 2*R, 6*Obutinib
Group 4:8*R-CHOP, 6*Obutinib
Sponsors
The First Affiliated Hospital of Medical College, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Understand and voluntarily sign the informed consent form; 2. The age ranged from 18 to 75 years (excluding the boundary value); 3. Pathological biopsy confirmed diffuse large B-cell lymphoma (tumor cells expressed CD20); 4. The patient has lesions that can be evaluated.
Exclusion criteria
Exclusion criteria: 1. Primary mediastinal large B-cell lymphoma, testicular lymphoma, or primary central large B-cell lymphoma; 2. Lymphoma with central involvement; 3. The patient has any serious medical condition that would cause the patient to develop an unbearable risk for participating in the study or require continued immunosuppressive therapy, such as unstable heart disease, stroke, rheumatoid arthritis, lupus, etc.; 4. Pregnant or lactating women; 5. History of malignancies other than lymphoma, unless the patient has been disease-free for more than 3 years; 6. The patient has an infectious or contagious disease (including HIV) that requires treatment; 7. The patient had previously received anti-lymphoma therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate, CRR;Event-free survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival time, OS;safety; | — |
Countries
China
Contacts
Public ContactHe Jingsong
The First Affiliated Hospital of Medical College, Zhejiang University
Outcome results
None listed